Global Assisted Reproductive Technologies Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Assisted Reproductive Technologies Drugs Market Research Report 2024
Assisted reproductive technology (ART) is used to treat infertility. It includes fertility treatments that handle both eggs and sperm. A number of different agents are used to achieve controlled ovarian hyperstimulation. These include clomiphene, GnRH analogues, menotropins, urofollitropin, highly purified FSH, and recombinant human FSH (rh-FSH), etc.
According to Mr Accuracy reports’s new survey, global Assisted Reproductive Technologies Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Assisted Reproductive Technologies Drugs market research.
Key companies engaged in the Assisted Reproductive Technologies Drugs industry include Merck, MSD, Ipsen, Ferring, Organon, Solvay, Besins, Zhejiang Xianju and Changchun GeneScience, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Assisted Reproductive Technologies Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Assisted Reproductive Technologies Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Assisted Reproductive Technologies Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Merck
MSD
Ipsen
Ferring
Organon
Solvay
Besins
Zhejiang Xianju
Changchun GeneScience
Hybio Pharmaceutical
Livzon Pharmaceutical
Segment by Type
Down-Regulation Drugs
Ovulation Stimulation Drugs
Ovulation Inducing Drugs
Luteal Support Medications
Hospital Pharmacy
Specialty & Retail Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Assisted Reproductive Technologies Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Assisted Reproductive Technologies Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Assisted Reproductive Technologies Drugs market research.
Key companies engaged in the Assisted Reproductive Technologies Drugs industry include Merck, MSD, Ipsen, Ferring, Organon, Solvay, Besins, Zhejiang Xianju and Changchun GeneScience, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Assisted Reproductive Technologies Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Assisted Reproductive Technologies Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Assisted Reproductive Technologies Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
MSD
Ipsen
Ferring
Organon
Solvay
Besins
Zhejiang Xianju
Changchun GeneScience
Hybio Pharmaceutical
Livzon Pharmaceutical
Segment by Type
Down-Regulation Drugs
Ovulation Stimulation Drugs
Ovulation Inducing Drugs
Luteal Support Medications
Segment by Application
Hospital Pharmacy
Specialty & Retail Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Assisted Reproductive Technologies Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source